.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Accenture
Healthtrust
Deloitte
Citi
Johnson and Johnson
Cerilliant
Baxter
Moodys

Generated: November 20, 2017

DrugPatentWatch Database Preview

Telaprevir - Generic Drug Details

« Back to Dashboard

What are the generic sources for telaprevir and what is the scope of telaprevir patent protection?

Telaprevir
is the generic ingredient in one branded drug marketed by Vertex Pharms and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telaprevir has one hundred and twenty-five patent family members in thirty-seven countries and twelve supplementary protection certificates in ten countries.

There are three drug master file entries for telaprevir.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: telaprevir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,923Peptidomimetic protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telaprevir

Country Document Number Estimated Expiration
Cyprus1109216► Subscribe
Russian Federation2393863► Subscribe
Germany122012000015► Subscribe
World Intellectual Property Organization (WIPO)0218369► Subscribe
Norway20100093► Subscribe
Ukraine99895► Subscribe
Spain2489115► Subscribe
European Patent Office1819336► Subscribe
China101693672► Subscribe
South Korea20080104382► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TELAPREVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
960Luxembourg► Subscribe91960, EXPIRES: 20260831
2012003Lithuania► SubscribePRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
12/009Ireland► SubscribePRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
90007-2Sweden► SubscribePRODUCT NAME: TELAPREVIR OCH FARMACEUTISKT GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919
2012003,C1320540Lithuania► SubscribePRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540/01Switzerland► SubscribeFORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US
C/GB12/010United Kingdom► SubscribePRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919
C0018France► SubscribePRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
2012 00007Denmark► Subscribe
2012 00007Denmark► SubscribePRODUCT NAME: TELAPREVIR OG FARMACEUTISK ACCEPTABLE SALTE OG/ELLER SOLVATER AF TELAPREVIR ELLER SOLVATER AF SADANNE SALTE; REG. NO/DATE: EU/1/11/720/001 20110919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
McKinsey
US Army
Merck
Queensland Health
Moodys
Daiichi Sankyo
Chubb
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot